BRPI0705396A2 - uso de compostos derivados ftalimìdicos e/ou sulfonamìdicos no tratamento de doenças em que há a necessidade de diminuição dos nìveis do fator tnf--(alfa) e a necessidade de uma fonte exógena de óxido nìtrico, compostos derivados ftalimìdicos, compostos derivados sulfonamìdicos, método de obtenção de um composto derivado sulfonamìdico - Google Patents

uso de compostos derivados ftalimìdicos e/ou sulfonamìdicos no tratamento de doenças em que há a necessidade de diminuição dos nìveis do fator tnf--(alfa) e a necessidade de uma fonte exógena de óxido nìtrico, compostos derivados ftalimìdicos, compostos derivados sulfonamìdicos, método de obtenção de um composto derivado sulfonamìdico

Info

Publication number
BRPI0705396A2
BRPI0705396A2 BRPI0705396-7A BRPI0705396A BRPI0705396A2 BR PI0705396 A2 BRPI0705396 A2 BR PI0705396A2 BR PI0705396 A BRPI0705396 A BR PI0705396A BR PI0705396 A2 BRPI0705396 A2 BR PI0705396A2
Authority
BR
Brazil
Prior art keywords
need
treatment
diseases
derived compounds
phthalimide
Prior art date
Application number
BRPI0705396-7A
Other languages
English (en)
Inventor
Santos Jean Leandro Dos
Chung Man Chin
Lidia Moreira Lima
Fernando Ferreira Costa
Carolina Lanaro
Original Assignee
Unicamp
Univ Estadual Paulista Julio D
Univ Rio De Janeiro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unicamp, Univ Estadual Paulista Julio D, Univ Rio De Janeiro filed Critical Unicamp
Priority to BRPI0705396-7A priority Critical patent/BRPI0705396B1/pt
Priority to US12/747,589 priority patent/US20100324107A1/en
Priority to CN2008801266024A priority patent/CN101951901B/zh
Priority to PCT/BR2008/000386 priority patent/WO2009073940A2/en
Priority to EP08859512A priority patent/EP2224922A4/en
Priority to KR1020107014045A priority patent/KR20100114880A/ko
Publication of BRPI0705396A2 publication Critical patent/BRPI0705396A2/pt
Priority to CO10083500A priority patent/CO6290640A2/es
Priority to ZA2011/08106A priority patent/ZA201108106B/en
Priority to US13/404,777 priority patent/US8338474B2/en
Priority to US13/404,634 priority patent/US8314255B2/en
Publication of BRPI0705396B1 publication Critical patent/BRPI0705396B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

USO DE COMPOSTOS DERIVADOS FTALIMìDICOS E/OU SULFONAMìDICOS NO TRATAMENTO DE DOENçAS EM QUE Há A NECESSIDADE DE DIMINUIçãO DOS NìVEIS DO FATOR TNF--<244> E A NECESSIDADE DE UMA FONTE EXóGENA DE óXIDO NìTRICO, COMPOSTOS DERIVADOS FTALIMìDICOS, COMPOSTOS DERIVADOS SULFONAMìDICOS, MéTODO DE OBTENçãO DE UM COMPOSTO DERIVADO SULFONAMìDICO. A presente invenção se refere ao uso de compostos derivados ftalimídicos e/ou sulfonamídicos com propriedades doadoras de óxido nítrico, os quais apresentam importantes atividades no aumento da expressão gênica de gama globina e atividades antiinflamatórias e analgésicas, potenciais ao tratamento de doenças hematológicas em que há a necessidade de diminuição dos níveis do fator TNF-<244> e a necessidade de uma fonte exógena de óxido nítrico. Mais particularmente, a presente invenção descreve o uso de tais derivados ftalimídicos e/ou sulfonamídicos para o tratamento de anemia falciforme. A invenção também apresenta como característica inovadora, a descrição de novos derivados ftalimídicos funcionalizados, desenhados a partir dos protótipos talidomida e hidroxiuréia e planejados racionalmente através da estratégia de hibridação molecular para o tratamento das doenças citadas. A invenção apresenta ainda um novo método de obtenção de um derivado sulfonamídico específico que pode ser utilizado na preparação de um medicamento para tratamento de doenças em que há a necessidade de diminuição dos níveis do fator TNF-<244> e a necessidade de uma fonte exógena de óxido nítrico
BRPI0705396-7A 2007-12-12 2007-12-12 Compostos derivados ftalimídicos BRPI0705396B1 (pt)

Priority Applications (10)

Application Number Priority Date Filing Date Title
BRPI0705396-7A BRPI0705396B1 (pt) 2007-12-12 2007-12-12 Compostos derivados ftalimídicos
KR1020107014045A KR20100114880A (ko) 2007-12-12 2008-12-12 질환의 치료에 있어서 프탈이미드 유도체의 용도
CN2008801266024A CN101951901B (zh) 2007-12-12 2008-12-12 酞酰亚胺衍生物在治疗疾病中的应用
PCT/BR2008/000386 WO2009073940A2 (en) 2007-12-12 2008-12-12 USE OF PHTHALIMIDE AND/OR SULPHONAMIDE DERIVATIVES IN THE TREATMENT OF DISEASES WHICH REQUIRE REDUCING THE TNF-α LEVELS AND AN EXOGENOUS SOURCE OF NITRIC OXIDE, PHTHALIMIDE DERIVATIVES, SULPHONAMIDE DERIVATIVES, AND A METHOD FOR OBTAINING A SULPHONAMIDE DERIVATIVE
EP08859512A EP2224922A4 (en) 2007-12-12 2008-12-12 USE OF PHTHALIMIDE AND / OR SULPHONAMIDE DERIVATIVES IN THE TREATMENT OF ILLNESSES FOR WHICH THE TNF MIRRORS MUST BE REDUCED, AND AN EXOGENIC STICK OXIDE SOURCE, PHTHALIMIDE DERIVATIVES, SULFONAMIDE DERIVATIVES, AND METHOD FOR OBTAINING A SULFONAMIDE DERIVATIVE
US12/747,589 US20100324107A1 (en) 2007-12-12 2008-12-12 USE OF PHTHALIMIDE AND/OR SULPHONAMIDE DERIVATIVES IN THE TREATMENT OF DISEASES WHICH REQUIRE REDUCING THE TNF-alpha LEVELS AND AN EXOGENOUS SOURCE OF NITRIC OXIDE, PHTHALIMIDE DERIVATIVES, SULPHONAMIDE DERIVATIVES, AND A METHOD FOR OBTAINING A SULPHONAMIDE DERIVATIVE
CO10083500A CO6290640A2 (es) 2007-12-12 2010-07-09 Uso de derivados de ftalimida y/o sulfonamida en el tratamiento de enfermedades que quieren reducir los niveles de tnf-a y una fuente exogena de oxido nitrico, derivados de ftalimida, derivados de sulfonamida y un método para obtener un derivado de s
ZA2011/08106A ZA201108106B (en) 2007-12-12 2011-11-04 Use of phthalimide derivatives in the treatment of diseases
US13/404,777 US8338474B2 (en) 2007-12-12 2012-02-24 Use of phthalimide and/or sulphonamide derivatives in the treatment of diseases which require reducing the TNF-α levels and an exogenous source of nitric oxide, phthalimide derivatives, sulphonamide derivatives, and a method for obtaining a sulphonamide derivative
US13/404,634 US8314255B2 (en) 2007-12-12 2012-02-24 Use of phthalimide and/or sulphonamide derivatives in the treatment of diseases which require reducing the TNF- α levels and an exogenous source of nitric oxide, phthalimide derivatives, sulphonamide derivatives, and a method for obtaining a sulphonamide derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0705396-7A BRPI0705396B1 (pt) 2007-12-12 2007-12-12 Compostos derivados ftalimídicos

Publications (2)

Publication Number Publication Date
BRPI0705396A2 true BRPI0705396A2 (pt) 2009-12-22
BRPI0705396B1 BRPI0705396B1 (pt) 2021-10-05

Family

ID=40755919

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0705396-7A BRPI0705396B1 (pt) 2007-12-12 2007-12-12 Compostos derivados ftalimídicos

Country Status (8)

Country Link
US (3) US20100324107A1 (pt)
EP (1) EP2224922A4 (pt)
KR (1) KR20100114880A (pt)
CN (1) CN101951901B (pt)
BR (1) BRPI0705396B1 (pt)
CO (1) CO6290640A2 (pt)
WO (1) WO2009073940A2 (pt)
ZA (1) ZA201108106B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3556401A1 (en) 2005-05-27 2019-10-23 The University of North Carolina at Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
ES2958410T3 (es) 2009-08-21 2024-02-08 Novan Inc Geles tópicos
EP2467173B8 (en) 2009-08-21 2019-06-19 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
WO2012118829A2 (en) 2011-02-28 2012-09-07 Novan, Inc. Tertiary s-nitrosothiol-modified nitricoxide-releasing xerogels and methods of using the same
WO2015108835A1 (en) * 2014-01-14 2015-07-23 Sarmont Llc 3,3-disubstituted-1-hydroxytriaz-1-ene 2-oxides and wound-healing compositions using them

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6137766A (ja) * 1984-07-31 1986-02-22 Sankyo Co Ltd フタルイミド誘導体およびその製造法
JPS6242967A (ja) * 1985-08-21 1987-02-24 Sankyo Co Ltd フタルイミド化合物およびその製造法
US5248785A (en) * 1990-02-12 1993-09-28 Virginia Commonwealth University Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood
NZ336035A (en) * 1996-11-05 2002-03-28 Childrens Medical Center Angiogenesis inhibitory composition comprising an inhibitory compound and antiinflammatory drug
CA2381205C (en) * 1999-08-02 2010-05-11 Duke University Method for determining physiological effects of hemoglobin
BR0316256A (pt) * 2002-11-18 2005-10-04 Celgene Corp Métodos de inibir a produção de tnf-alfa e a atividade de pde4, de tratar ou prevenir uma doença ou um distúrbio, de controlar os nìveis de camp em uma célula e de produzir um composto, composição farmacêutica e composto
CA2518513C (en) * 2003-03-12 2014-05-20 Celgene Corporation N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses
MXPA06006061A (es) * 2003-12-02 2006-08-11 Celgene Corp Metodos y composiciones para el tratamiento y manejo de la hemoglinopatia y la anemia.

Also Published As

Publication number Publication date
US8314255B2 (en) 2012-11-20
EP2224922A2 (en) 2010-09-08
CN101951901A (zh) 2011-01-19
ZA201108106B (en) 2013-07-31
BRPI0705396B1 (pt) 2021-10-05
WO2009073940A2 (en) 2009-06-18
KR20100114880A (ko) 2010-10-26
US20120157690A1 (en) 2012-06-21
US20120245364A1 (en) 2012-09-27
US20100324107A1 (en) 2010-12-23
EP2224922A4 (en) 2010-12-22
WO2009073940A3 (en) 2009-11-12
CN101951901B (zh) 2012-11-28
US8338474B2 (en) 2012-12-25
CO6290640A2 (es) 2011-06-20

Similar Documents

Publication Publication Date Title
Kura et al. Oxidative stress-responsive microRNAs in heart injury
Pena et al. Oxidative stress, kinase activity and inflammatory implications in right ventricular hypertrophy and heart failure under hypobaric hypoxia
BRPI0705396A2 (pt) uso de compostos derivados ftalimìdicos e/ou sulfonamìdicos no tratamento de doenças em que há a necessidade de diminuição dos nìveis do fator tnf--(alfa) e a necessidade de uma fonte exógena de óxido nìtrico, compostos derivados ftalimìdicos, compostos derivados sulfonamìdicos, método de obtenção de um composto derivado sulfonamìdico
Di Francia et al. Response and toxicity to cytarabine therapy in leukemia and lymphoma: from dose puzzle to pharmacogenomic biomarkers
Gao et al. CYP3A4* 1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin
BRPI0510394A (pt) inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1
BR112012027062B8 (pt) composto, processo para a preparação de um composto e usos do mesmo
UY29410A1 (es) Composiciones farmacéuticas en base a metilamidas del ácido 4-(4-/-3(-4-cloro-3-trifluorometifenil)ureido)fenoxi)piridin-2-carboxílico, procedimiento de preparación y aplicaciones.
Marrazzo et al. Combined treatment with three natural antioxidants enhances neuroprotection in a SH-SY5Y 3D culture model
Dhingra et al. Succinate dehydrogenase/complex II activity obligatorily links mitochondrial reserve respiratory capacity to cell survival in cardiac myocytes
DE602004030017D1 (de) Heterocyclische verbindungen als nützliche malonyl-coa decarboxylase-hemmer
Guerrero-Orriach et al. Heart failure after cardiac surgery: the role of halogenated agents, myocardial conditioning and oxidative stress
Musayeva et al. Betulinic acid protects from ischemia-reperfusion injury in the mouse retina
Kuo et al. Metformin results in diametrically opposed effects by targeting non-stem cancer cells but protecting cancer stem cells in head and neck squamous cell carcinoma
De Nicolo et al. Calcium and reactive oxygen species signaling interplays in cardiac physiology and pathologies
Ebeid et al. PIM1 promotes survival of cardiomyocytes by upregulating c-kit protein expression
Chronopoulos et al. Effects of resveratrol on vascular function in retinal ischemia-reperfusion injury
BRPI0602397C1 (pt) composições farmacêuticas para o tratamento das doenças gordurosas do fìgado, obesidade e demais doenças associadas à sìndrome metabólica e métodos de tratamento utilizando-se as referidas composições
Guzman et al. An iterative process produces oxamniquine derivatives that kill the major species of schistosomes infecting humans
Ward et al. Chronic activation of AMP‐activated protein kinase prevents 20‐hydroxyeicosatetraenoic acid‐induced endothelial dysfunction
Xiao et al. Activation of Wnt/β-catenin signaling involves 660 nm laser radiation on epithelium and modulates lipid metabolism
Pampanella et al. Cytochalasin B influences cytoskeletal organization and osteogenic potential of human Wharton’s jelly mesenchymal stem cells
Kuvarzin et al. Unlocking the therapeutic potential of ulotaront as a trace amine-associated receptor 1 agonist for neuropsychiatric disorders
Nowakowska et al. Biological response induced in primary human gingival fibroblasts upon exposure to various types of injectable astringent retraction agents
EA200970506A1 (ru) Применение индазолметоксиалкановой кислоты для снижения уровней триглицеридов, холестерина и глюкозы

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO EM SUA FORMA AUTENTICADA; OU SEGUNDO MEMO/INPI/PROC/NO 074/93, DEVE CONSTAR UMA DECLARACAO DE VERACIDADE, A QUAL DEVE SER ASSINADA POR UMA PESSOA DEVIDAMENTE AUTORIZADA A REPRESENTAR O INTERESSADO, DEVENDO A MESMA CONSTAR NO INSTRUMENTO DE PROCURACAO, OU NO SEU SUBSTABELECIMENTO.

B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/12/2007, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.